EICHORPublic-registry site landscape for NCT06382662, “Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition”, a Cognitive Impairment study sponsored by Primus Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06382662 (registry record) |
| Study title | Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition |
| Official title | Assessment of the Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Tizanidine 8 mg: A Prospective, Single-blind, Within-subject Pilot Study |
| Sponsor | Primus Pharmaceuticals |
| Condition(s) | Cognitive Impairment |
| Phase | PHASE4 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06382662.
Eichor generates a preliminary site-risk snapshot for NCT06382662 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Cognitive Impairment trials
More from Primus Pharmaceuticals
← Eichor home · All tracked trials · Cognitive Impairment studies · Weekly briefs
